Chitose Supercell will revolutionise the world’s antibody drug manufacturing process

cell engineering, antibody drug manufacturing, biologics manufacturing, master cell bank development, cell line development, CHO cell, mammalian cell line

“We want to implement a platform into the world so that medical supplies can be prescribed more easily ”

In the world, the need for regenerative medicine or unmet medical (illnesses for which no cure has been found) is increasing everyday. Chitose is aiming to speed up and reduce costs of the world’s antibiotics manufacturing process by using a super cell to contribute to the global healthcare.
As a leader in the host cell market, we will develop new CHO cells that boast the world's highest production efficiency of antibody drugs, participate in the AMED business, and collaborate with domestic and overseas biopharmaceutical companies.

Background issues

In order to reduce the price of antibody drugs, which are ever soaring, high efficiency and low manufacturing process costs are required.

Our technologies

Technology to create diversity in a uniform cell pool and develop cells with several outstanding characteristics
Technology to screen for cells with desired characteristics from various cell pools
Technology to establish immortalized cell lines from primary tissue culture
Technology to develop test methods to comply with regulations for drug application

Current status

Through collaboration or consigned development with domestic and international pharmaceutical companies, we continue to produce new cell lines.
As a member of Manufacturing Technology Association of Biologics (MAB, AMED project), we are in charge of constructing the cell bank.

Locations

Japan

partner

Manufacturing Technology Association of Biologics (AMED)

MessagePICK UP PERSON

Noboru Osawa

I am engaged in businesses related to biologics using animal cell lines at Chitose Laboratory. Biologics here refers mainly to the production of biopharmaceuticals such as antibodies and other proteins. Currently we are working on developing cells that are exceptional for antibody production, and to embed the new platform in the world so that biopharmaceuticals can be prescribed more easily.